Citizens Maintains Market Outperform on BioCryst Pharma, Raises Price Target to $28

Citizens analyst Jonathan Wolleben maintains BioCryst Pharma (NASDAQ:BCRX) with a Market Outperform and raises the price target from $25 to $28.